HCA-7 Xenograft Model Service for Colon Cancer

The HCA-7 xenograft model serves as a robust preclinical platform for colon cancer research, enabling precise evaluation of therapeutic efficacy and tumor biology in an immunodeficient host environment. Alfa Cytology offers comprehensive HCA-7 xenograft model services tailored to accelerate your preclinical drug development pipeline, delivering reliable tumor growth data and mechanistic insights through standardized, quality-controlled protocols.

Overview of HCA-7 Xenograft Model for Colon Cancer

The HCA-7 cell line was originally established in 1985 by Kirkland from a primary human colonic adenocarcinoma resected from a 58-year-old female patient, classified as Dukes' stage B with moderately differentiated histology. HCA-7 cells exhibit epithelial morphology, secrete carcinoembryonic antigen (CEA), and retain structural and functional polarity characteristic of normal colonic epithelium, including the formation of polarized monolayers with apical tight junctions and desmosomes. A distinctive feature of this cell line is its ability to form "domes" or "hemicysts" in confluent monolayers due to vectorial fluid transport, reflecting preserved transepithelial transport function. HCA-7 demonstrates strong tumorigenicity in immunodeficient mice, forming well-differentiated adenocarcinomas upon subcutaneous inoculation, making it a valuable model for studying colon cancer progression, drug response, and epithelial biology.

HCA-7 cells express high levels of cyclooxygenase-2 (COX-2) and microsomal prostaglandin E synthase-1 (mPGES-1), which are clinically relevant targets in colorectal cancer therapeutics. The cell line carries key genetic alterations including APC mutations, TP53 mutations, and a defective mismatch repair (MMR) system with MSH3 mutation and MLH1 hypermethylation, while remaining wild-type for KRAS. These molecular characteristics closely mirror the genetic landscape of human colorectal adenocarcinomas, particularly those associated with sporadic microsatellite instability. In xenograft applications, HCA-7 tumors have been extensively utilized to evaluate novel therapeutic strategies, including fatty acid metabolism interventions, COX-2-targeted therapies, and combination regimens with standard chemotherapeutics such as 5-fluorouracil, providing a physiologically relevant platform for preclinical pharmacology studies.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting colorectal adenocarcinoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving colon cancer progression through COX-2 and mPGES-1 expression, and how treatments intersect with defective mismatch repair pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment, particularly for CEA and COX-2-related markers.

Figure 1. Morphology of HCA-7 cells exposed to different NM concentrations. (Roomi, M. W., et al., 2019)

Cell Line Information: HCA-7

The HCA-7 cell line is a well-established human colorectal adenocarcinoma line with comprehensive molecular characterization. Its ability to form polarized monolayers with dome formation, high COX-2 expression, and defective mismatch repair status make it unique among available colon cancer cell lines and essential for preclinical research targeting epithelial biology and COX-2-driven colorectal carcinoma.

Our Services

Alfa Cytology leverages the HCA-7 xenograft model to provide end-to-end preclinical research services, from tumor establishment and in-life monitoring to endpoint analysis and histopathological evaluation, ensuring reproducible data that supports your compound's progression from bench to bedside.

Workflow of HCA-7 Xenograft Model Construction

The construction of the HCA-7 xenograft model follows a standardized, multi-step protocol designed to ensure consistent tumor take rates, reproducible growth kinetics, and reliable pharmacological readouts. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Culture and Expansion: HCA-7 cells are expanded under adherent culture conditions in DMEM supplemented with 10% FBS and 2 mM glutamine at 37 degrees C with 5% CO2. Cells are maintained at sub-confluent density (70--80%) and passaged using 0.05% trypsin/EDTA to preserve viability and tumorigenic potential.
2. Quality Control Verification: Prior to inoculation, cells undergo comprehensive quality control including mycoplasma testing, sterility verification, and STR authentication to confirm cell line identity. Viability is assessed by trypan blue exclusion, with only cultures exceeding 95% viability selected for xenograft establishment.
3. Cell Harvest and Preparation: HCA-7 cells are harvested at logarithmic growth phase, washed with PBS, and resuspended in serum-free DMEM or Matrigel mixture at a concentration optimized for tumor establishment (typically 2--5 x 10^6 cells per 100--200 uL injection volume).
4. Animal Preparation and Inoculation: Immunodeficient mice (commonly athymic nude or NOD-SCID) are acclimatized for one week under pathogen-free conditions. HCA-7 cell suspensions are injected subcutaneously into the hind flank or dorsal region using a sterile technique, with tumor take rates typically exceeding 90% under optimized conditions.
5. Tumor Monitoring and Growth Assessment: Tumor development is monitored twice weekly by digital caliper measurement. Tumor volume is calculated using the formula V = L x W^2 / 2. Mice are randomized into treatment groups once tumors reach a predetermined size (typically 100--200 mm^3), ensuring balanced baseline tumor volumes across cohorts.
6. Treatment Administration and In-Life Monitoring: Test compounds are administered according to the study design (oral gavage, intravenous injection, or intraperitoneal injection). Body weight, clinical signs, and tumor dimensions are recorded throughout the treatment period to assess compound efficacy and tolerability.
7. Endpoint Analysis and Tissue Collection: At study termination, mice are euthanized humanely. Tumor tissues are excised, weighed, and photographed. Tumor growth inhibition (TGI) is calculated relative to vehicle control. Tissues are processed for histopathology (H&E staining), immunohistochemistry (IHC), biomarker analysis, and molecular profiling as required.
8. Data Compilation and Reporting: All raw data are compiled into a comprehensive study report including tumor growth curves, body weight trajectories, TGI calculations, histopathological images, and statistical analyses, delivered in a format ready for regulatory submission or publication.

Figure 2: Schematic workflow illustrating the derivation and construction of the HCA-7 Xenograft Model at Alfa Cytology.

Case Study-HCA-7 Xenograft Model Development

Alfa Cytology has successfully established and validated the HCA-7 xenograft model across multiple independent studies, demonstrating consistent tumor take rates, predictable growth kinetics, and robust responsiveness to reference compounds. Our internal dataset encompasses tumor growth curves, pharmacokinetic-pharmacodynamic correlations, and biomarker modulation profiles, all generated under GLP-compliant quality standards. Specific quantitative data and representative case study results are available upon request under confidentiality agreements to protect proprietary client information and ongoing research programs. Please contact our scientific team to discuss your specific project requirements and receive tailored data packages.

Why Choose Alfa Cytology?

Alfa Cytology delivers precision, reliability, and scientific rigor in every HCA-7 xenograft study, ensuring your preclinical data withstands the scrutiny of regulatory review and peer evaluation.

• Verified Cell Line Integrity: Validated HCA-7 cell stocks with authenticated STR profiles and confirmed tumorigenicity in immunodeficient mice.
• High Take Rates and Consistency: Standardized xenograft protocols optimized for consistent tumor take rates and reproducible pharmacological readouts.
• Comprehensive Analytical Support: Comprehensive in-life monitoring including tumor caliper measurements, body weight tracking, and clinical observation.
• Tailored Study Designs: Flexible endpoint analysis encompassing histopathology, immunohistochemistry, biomarker quantification, and molecular profiling.
• Standardized Protocols: Dedicated project management with timely reporting and transparent communication throughout the study lifecycle.
• Dedicated Project Management: Cost-effective service packages tailored to early-stage discovery, lead optimization, and IND-enabling studies.

Contact Us

Ready to advance your colon cancer therapeutic program with the HCA-7 xenograft model? Reach out to Alfa Cytology today to discuss your project specifications, receive a customized study proposal, and partner with a CRO committed to accelerating your preclinical success. Our scientific team is standing by to provide expert guidance from study design through data delivery---contact us now to get started. Please reach out to us today via our inquiry form or email to learn more about our HCA-7 Xenograft Model services.

For research use only. Not intended for any clinical use.